Frontiers in Immunology (Jan 2024)
Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
- Xinghui Xiao,
- Xinghui Xiao,
- Ying Cheng,
- Ying Cheng,
- Xiaodong Zheng,
- Xiaodong Zheng,
- Yuhang Fang,
- Yuhang Fang,
- Yu Zhang,
- Yu Zhang,
- Rui Sun,
- Rui Sun,
- Zhigang Tian,
- Zhigang Tian,
- Zhigang Tian,
- Haoyu Sun,
- Haoyu Sun
Affiliations
- Xinghui Xiao
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Xinghui Xiao
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Ying Cheng
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Ying Cheng
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Xiaodong Zheng
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Xiaodong Zheng
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Yuhang Fang
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Yuhang Fang
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Yu Zhang
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Yu Zhang
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Rui Sun
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Rui Sun
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Zhigang Tian
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Zhigang Tian
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- Zhigang Tian
- Hefei TG ImmunoPharma Corporation Limited, Hefei, China
- Haoyu Sun
- Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- Haoyu Sun
- Institute of Immunology, University of Science and Technology of China, Hefei, China
- DOI
- https://doi.org/10.3389/fimmu.2024.1365027
- Journal volume & issue
-
Vol. 15
Abstract
No abstracts available.Keywords
